Newscast – Page 86 – media

RapidSOS collects $16M to deliver stronger data to emergency response teams

RapidSOS, a five-year-old startup focused on updating emergency response systems with data-driven technology, has raised $16 million in funding from Highland Capital, Microsoft Ventures, and CSAA Insurance Group, according to a statement. Forté Ventures also contributed.
- Source: MobiHealthNews
- 474
- April 23, 2018
Company Insights digital health healthcare
The 3 most valuable applications of AI in health care

A recent report from Accenture analyzed the “near-term value” of AI applications in health care to determine how the potential impact of the technology stacks up against the upfront costs of implementation. Results from the report estimated that AI applications in health care could save up to $150 billion annually for the U.S. health care economy by 2026.
- Source: Venture Beats
- 708
- April 23, 2018
AI digital health Market Views
Amid tough respiratory competition, AstraZeneca inks Symbicort outcomes-based deals

It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share.
- Source: fiercepharma
- 646
- April 20, 2018
AstraZeneca Company Insights Symbicor
BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development

BenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector.
- Source: benevolent.ai
- 572
- April 20, 2018
AI Company Insight
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures

The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meeting
- Source: prnewswire
- 647
- April 20, 2018
Amgen migraine
Hanmi Pharma gives up on development of lung cancer drug Olita

South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
- Source: koreaher
- 2,372
- April 20, 2018
Clinical Trials Company Insights Olita
After successful pilot, Boehringer Ingelheim, HealthPrize roll out digital adherence tool more broadly

Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
- Source: MobiHealthNews
- 574
- April 20, 2018
Boehringer Ingelheim Company Insights digital health
Which features of healthcare apps do patients desire most?

A new survey from customer experience agency Verndale found consumers most strongly want healthcare apps to provide the ability to manage appointments. Other most desired features among all patients include providing an alert when an appointment is running late, the ability to refill prescriptions and access to medical records.
- Source: MedCityNews
- 764
- April 20, 2018
healthcare Market Views mHealth
Carpe Secures $2.3M Seed Funding

Carpe, a skincare startup offering over-the-counter relief for excessive hand and foot sweating to the estimated 365 million hyperhidrosis sufferers worldwide, announced today that it has raised $2.3 million in seed funding. The round was co-led by the Carolina Angel Network and Duke Angel Network, affiliated with the University of North Carolina and Duke University's alumni networks respectively. Other investors include LaunchCapital, Rubicon Venture Capital, and Triangle Angel Partners.
- Source: vcnewsdaily
- 692
- April 19, 2018
Hyperhidrosis Market Views Series
J&J buys into Bristol-Myers cardiovascular disease program

Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
- Source: Fiercebiotech
- 2,268
- April 19, 2018
anticoagulants inhibitor Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.